MedTrace Logo

Tirofiban With Sequential Dual Antiplatelet Therapy in Mild Stroke

NCT07095790 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 580

Last updated 2025-07-31

No results posted yet for this study

Summary

This study aims to evaluate whether initiating intravenous tirofiban within 48 hours of onset (with a 48-hour infusion), followed by sequential DAPT, can improve the likelihood of excellent functional outcomes (modified Rankin Scale score 0-1) in mild stroke patients, compared with standard DAPT therapy based on current guidelines.

Conditions

  • Mild Stroke

Interventions

DRUG

Tirofiban+Oral Dual Antiplatelet Therapy

Tirofiban will use a loading dose, 0.4 μg/kg/min × 30 minutes, then 0.1μg/kg/min infusion for 47.5 hours; sequential Oral Dual Antiplatelet Therapy (Aspirin 100mg qd; Clopidogrel 75mg qd)

DRUG

Oral Dual Antiplatelet Therapy

Aspirin 100mg qd; Clopidogrel 75mg qd (after first dose of 300mg)

Sponsors & Collaborators

  • Second Affiliated Hospital of Soochow University

    lead OTHER

Principal Investigators

  • Jijun Shi, M.D · Second Affiliated Hospital of Soochow University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-30
Primary Completion
2027-02-28
Completion
2027-05-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07095790 on ClinicalTrials.gov